



PRESS RELEASE

MolMed: outcome of the Shareholder's Meeting held on October 25th 2018

The Board of Directors has been delegated to increase the share capital with the exclusion of the pre-emption right, within 24 months, up to 10%

Reduced the number of the members of the Board of Directors from eleven to ten.

Milan (Italy), October 25th 2018 – MolMed S.p.A. (MLMD.MI) (the “Company”), clinical stage biotechnology company focusing on research, development, manufacturing, and clinical validation of cell & gene therapies to treat cancer and rare diseases, announces that the Shareholders’ Meeting held today and chaired by dott. Carlo Incerti, resolved upon the following items of the agenda:

Delegation to increase the share capital with the exclusion of the pre-emption right up to 10%.

The Extraordinary Shareholders’ Meeting of the Company, acknowledging the Board of Directors’ reports, resolved to delegate to the Board of Directors, pursuant to Article 2443 of the Italian Civil Code, the power to increase the share capital, in one or several *tranches*, within 24 months, by cash and in divisible way, with the exclusion of the pre-emption right pursuant to Article 2441, paragraph 4, second part, of the Italian Civil Code, by the issue of a number of ordinary shares, with no par value, not exceeding the 10% of the overall number of shares representing MolMed’s share capital of as of the date of the exercise of the delegated powers.

Please note that the delegation to the Board of Directors is justified by the opportunity to maintain and assign the power to implement possible operations upon the share capital to the directors, throughout faster and more flexible procedures compared with the extraordinary shareholders’ meeting resolutions, aimed to the enforcement of the financial structure supporting the Company’s development goals.

The proceeds of the possible capital increase will be used – as already disclosed to the public – for the clinical development of the most advanced proprietary products, the new pipeline development (recently enriched with CAR therapies both autologous as well as allogeneic), to maintain a high standard of facilities as well as, more generally, for the needs of the Company’s business.

For more information on the capital increase subject to the delegation, please refer to the "*Relazione Illustrativa sulla proposta di delega per l'aumento di capitale*" (only in Italian) published on the website <http://www.molmed.com> in Investors / Shareholder information / Shareholders Meetings section.

Appointment of a new director or reduction of the number of the members of the Board of Directors

The Ordinary Shareholders’ Meeting, acknowledging that prof. Claudio Bordignon’s resigned from his office as director of the Company, resolved to reduce the number of the members of the Board of Directors from eleven to ten.



PRESS RELEASE

Documentation filing

In accordance with the provisions of Article 125-*quater*, paragraph 2, of the Italian Consolidated Finance Act (*Testo Unico della Finanza*) (Legislative Decree no. 58/1998, as subsequently amended and Article 77, paragraph 3, of the Issuers' Regulations (*Regolamento Emittenti*), a summary report containing the number of voting shares represented at the meeting and the actions for which the vote was cast, the percentage of capital that these shares represent, as well as the number of votes for and against the resolutions and the number of abstentions, will be made available to the public within five days from the date of the Shareholders' meeting on the Company's website.

The minutes of the Shareholders' Meeting will be made available to the public according to the terms provided by the laws and regulations in force.

This press release is available on the Company's website <http://www.molmed.com>

About MolMed

MolMed S.p.A. is a clinical stage biotech company focused on research, development, manufacturing and clinical validation of innovative anticancer therapies. MolMed's product portfolio includes proprietary anti-tumor therapies in both clinical and preclinical development: Zalmoxis® (TK) is a cell therapy based on donor T cells genetically engineered to enable bone marrow transplants from partially compatible donors for patients with high-risk hematological malignancies, eliminating post-transplant immunosuppression prophylaxis and inducing a rapid immune reconstitution. Zalmoxis® received Orphan Drug Designation and is currently in Phase III in a high-risk population of acute leukemia patients, but has already obtained a Conditional Marketing Authorization by the European Commission in the second half of 2016 as well as reimbursement conditions in Italy at the end of 2017 and in Germany at the beginning of 2018. Still focusing on this cell & gene technology, the company is developing a new CAR pipeline based on Chimeric Antigen Receptor; the most advanced product, the CAR-T CD44v6, currently in advanced preclinical development, and is potentially effective both for some hematological malignancies and several solid epithelial tumors. Following the authorization request submitted to European Regulatory Agencies, MolMed plans to commence during the first half of 2019, human clinical trials in the AML and MM indications. In addition, the Company is developing a new CAR pipeline, both autologous and allogeneic, the last one based on NK (Natural Killer) cells. is also the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies for its proprietary products



PRESS RELEASE

(Zalmoxis®) as well as for third parties and/or in partnership (Strimvelis, an Orchard gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso.

For further information:

Ilaria Candotti

Investor Relations & Communication Manager

MolMed S.p.A.

+39 02 21277.205

+39 02 21277.325

investor.relations@molmed.com

Marcella Ruggiero

Press agent

SEC Relazioni Pubbliche e Istituzionali s.r.l.

+39 02 6249991

+39 335 214241

ruggiero@secrp.com